论文部分内容阅读
近年来,随着医学技术的进步,2型糖尿病治疗药物不断出现,当前关于2型糖尿病治疗药物的研究重点正在发生一定的转移,即从传统致病机制的治疗逐步转移到对新治病机制与靶点的治疗上。由于2型糖尿病患者体内胰岛β细胞的功能存在某种程度的衰退,因此治疗药物应重点从该处应着手突破。本文基于国内外相关文献研究现状,分析了胰高血糖素样肽-I类似物、二肽基肽酶-IV抑制剂等药物的研究新进展。
In recent years, with advances in medical technology, type 2 diabetes treatment drugs continue to emerge, the current focus on type 2 diabetes treatment drug research is undergoing some transfer, that is, from the traditional pathogenic mechanism of treatment gradually shifted to the new mechanism of the disease With the target of treatment. Because type 2 diabetes patients with pancreatic β-cell function there is a certain degree of decline, so the treatment should focus on medicine from here to break through. Based on the current research situation in related literatures both at home and abroad, the research progress of glucagon-like peptide-I analogs, dipeptidyl peptidase-IV inhibitors and other drugs are analyzed.